Joseph Piscitelli
Research Subjects
Joseph Piscitelli has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Lance Wollenberg
Pfizer Inc., San Diego, USA
5 shared publicationsMicaela B. Reddy
Pfizer Inc., San Diego, USA
4 shared publicationsJason Gong
Pfizer Inc New York New York USA
3 shared publicationsLaurence Del Frari
Pierre Fabre Medicament, Toulouse, France
3 shared publicationsErik Hahn
Pfizer Inc., San Diego, USA
2 shared publicationsKyle Matschke
Pfizer Inc, Collegeville, USA
2 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (9) , 1367-1376
The Effect of Food and the Proton Pump Inhibitor Rabeprazole on Binimetinib Pharmacokinetics in Healthy Participants
- 27 July 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (9) , 1367-1376
Open AccessThe Effect of Food and the Proton Pump Inhibitor Rabeprazole on Binimetinib Pharmacokinetics in Healthy Participants
- Open Access
- 12 March 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (5) , 693-707
Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model
Encorafenib is a potent and selective adenosine triphosphate-competitive BRAF V600-mutant kinase inhibitor. Encorafenib is approved for multiple indications in combination with binimetinib or cetuximab. This analysis aimed to develop a global population pharmacokinetics (popPK) model characterizing encorafenib disposition across tumor types. The popPK analysis was based on nine phase 1 to 3 studies in participants with melanoma, colorectal cancer (CRC), non-small cell lung cancer, or other solid tumors, and healthy participants. A total of 1310 participants who received encorafenib as monotherapy or in combination were included. Nonlinear mixed effects modeling was performed using NONMEM v7.5.0. A semi-mechanistic enzyme turnover model was assessed to quantify the autoinduction effect. Stepwise covariate modeling using Perl-speaks-NONMEM (version 5.3.0) evaluated a broad range of covariates. A two-compartment model with first-order absorption and concentration-dependent autoinduction successfully characterized the concentration-time profile of encorafenib. Encorafenib apparent clearance (CL/F) was estimated to be 12.2 L/h after the first dose in a typical adult and increased by 186% to 35 L/h at steady state. This model indicates that maximum autoinduction is expected within 14 days of daily dosing (autoinduction half-life 64 h). Age and tumor type (melanoma, metastatic CRC, other [healthy, lung tumors, other solid tumors]) on CL/F and body weight on volume of distribution were significant covariates; these effects were not determined to be clinically significant. This model successfully described the PK of encorafenib over time and across tumor types. No dose modifications are suggested on the basis of intrinsic or extrinsic factors evaluated.
- 12 March 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (5) , 693-707
Open AccessPopulation Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model
Encorafenib is a potent and selective adenosine triphosphate-competitive BRAF V600-mutant kinase inhibitor. Encorafenib is approved for multiple indications in combination with binimetinib or cetuximab. This analysis aimed to develop a global population pharmacokinetics (popPK) model characterizing encorafenib disposition across tumor types. The popPK analysis was based on nine phase 1 to 3 studies in participants with melanoma, colorectal cancer (CRC), non-small cell lung cancer, or other solid tumors, and healthy participants. A total of 1310 participants who received encorafenib as monotherapy or in combination were included. Nonlinear mixed effects modeling was performed using NONMEM v7.5.0. A semi-mechanistic enzyme turnover model was assessed to quantify the autoinduction effect. Stepwise covariate modeling using Perl-speaks-NONMEM (version 5.3.0) evaluated a broad range of covariates. A two-compartment model with first-order absorption and concentration-dependent autoinduction successfully characterized the concentration-time profile of encorafenib. Encorafenib apparent clearance (CL/F) was estimated to be 12.2 L/h after the first dose in a typical adult and increased by 186% to 35 L/h at steady state. This model indicates that maximum autoinduction is expected within 14 days of daily dosing (autoinduction half-life 64 h). Age and tumor type (melanoma, metastatic CRC, other [healthy, lung tumors, other solid tumors]) on CL/F and body weight on volume of distribution were significant covariates; these effects were not determined to be clinically significant. This model successfully described the PK of encorafenib over time and across tumor types. No dose modifications are suggested on the basis of intrinsic or extrinsic factors evaluated.
- Open Access
- 10 November 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (2) , 375-380
An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered as a cocktail (Inje). This study was conducted, post‐approval, in patients with BRAF V600‐mutant advanced solid tumors, and aimed to address the remaining uncertainty in the DDI potential of encorafenib as a perpetrator of these CYP enzymes. Study participants received the cocktail on Days −7, 1, and 14 and continuous doses of encorafenib (450 mg q.d.) and binimetinib (45 mg b.i.d.) starting on Day 1. PK sampling and urine collection were conducted from 0 to 8 hours on cocktail administration days. PK parameters were calculated for each participant using noncompartmental analysis of concentration–time data or amount excreted for urine parameters. At steady‐state encorafenib plasma concentrations, midazolam plasma C max and AUC last decreased by 74% and 82%, respectively. No clinically significant DDIs were observed at encorafenib steady‐state concentrations with the other probe substrates of interest. The results from this clinical study indicate that encorafenib is a strong inducer of CYP3A (≥ 80% decrease in midazolam area under the curve (AUC)) at steady state. Based on these results regarding co‐administration with encorafenib, sensitive substrates of CYP3A should be avoided or dose adjusted based on the recommendations of their approved product labeling. This information has been included in the updated prescribing information for encorafenib.
- 10 November 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (2) , 375-380
Open AccessAn Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered as a cocktail (Inje). This study was conducted, post‐approval, in patients with BRAF V600‐mutant advanced solid tumors, and aimed to address the remaining uncertainty in the DDI potential of encorafenib as a perpetrator of these CYP enzymes. Study participants received the cocktail on Days −7, 1, and 14 and continuous doses of encorafenib (450 mg q.d.) and binimetinib (45 mg b.i.d.) starting on Day 1. PK sampling and urine collection were conducted from 0 to 8 hours on cocktail administration days. PK parameters were calculated for each participant using noncompartmental analysis of concentration–time data or amount excreted for urine parameters. At steady‐state encorafenib plasma concentrations, midazolam plasma C max and AUC last decreased by 74% and 82%, respectively. No clinically significant DDIs were observed at encorafenib steady‐state concentrations with the other probe substrates of interest. The results from this clinical study indicate that encorafenib is a strong inducer of CYP3A (≥ 80% decrease in midazolam area under the curve (AUC)) at steady state. Based on these results regarding co‐administration with encorafenib, sensitive substrates of CYP3A should be avoided or dose adjusted based on the recommendations of their approved product labeling. This information has been included in the updated prescribing information for encorafenib.
- Open Access
- 23 June 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (8) , 1217-1230
Pharmacokinetics of Binimetinib in Participants with Hepatic Impairment
Binimetinib is approved for multiple indications at a therapeutic dose of 45 mg twice a day (BID), in combination with encorafenib. A clinical hepatic impairment (HI) study was designed to evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of binimetinib in participants with mild, moderate, and severe HI compared with demographically matched healthy participants with respect to age, gender, and body weight. Participants were enrolled according to National Cancer Institute (NCI) classification criteria for hepatic function based on their total bilirubin and aspartate aminotransferase levels at screening. Participants enrolled into Group 1 (normal hepatic function) were matched to participants enrolled into Groups 2, 3, and 4 (mild, moderate, and severe HI, respectively) with respect to age, gender, and body weight. Dose-normalized PK parameters were evaluated because of a difference in doses for the severe HI group compared to the other groups, with the dose reduction due to the increased exposures observed in the moderate HI group. Among 27 PK evaluable participants, changes in binimetinib dose-normalized PK parameters Cmax/D and AUCinf/D were minimal in participants with mild HI compared to the normal hepatic function group. Both the moderate and severe HI groups had significant changes as AUCinf/D increased by 81% and 111%, respectively, compared to the normal hepatic function group. Unbound AUClast/D for the moderate and severe HI groups increased by 280% and 248% compared to the normal hepatic function group, respectively. Based on these findings on total and unbound exposures, dose reductions are recommended for binimetinib in cancer patients with moderate and severe HI. ClinicalTrials.gov NCT02050815, registered 29 January 2014.
- 23 June 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (8) , 1217-1230
Open AccessPharmacokinetics of Binimetinib in Participants with Hepatic Impairment
Binimetinib is approved for multiple indications at a therapeutic dose of 45 mg twice a day (BID), in combination with encorafenib. A clinical hepatic impairment (HI) study was designed to evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of binimetinib in participants with mild, moderate, and severe HI compared with demographically matched healthy participants with respect to age, gender, and body weight. Participants were enrolled according to National Cancer Institute (NCI) classification criteria for hepatic function based on their total bilirubin and aspartate aminotransferase levels at screening. Participants enrolled into Group 1 (normal hepatic function) were matched to participants enrolled into Groups 2, 3, and 4 (mild, moderate, and severe HI, respectively) with respect to age, gender, and body weight. Dose-normalized PK parameters were evaluated because of a difference in doses for the severe HI group compared to the other groups, with the dose reduction due to the increased exposures observed in the moderate HI group. Among 27 PK evaluable participants, changes in binimetinib dose-normalized PK parameters Cmax/D and AUCinf/D were minimal in participants with mild HI compared to the normal hepatic function group. Both the moderate and severe HI groups had significant changes as AUCinf/D increased by 81% and 111%, respectively, compared to the normal hepatic function group. Unbound AUClast/D for the moderate and severe HI groups increased by 280% and 248% compared to the normal hepatic function group, respectively. Based on these findings on total and unbound exposures, dose reductions are recommended for binimetinib in cancer patients with moderate and severe HI. ClinicalTrials.gov NCT02050815, registered 29 January 2014.
- Open Access
- 15 June 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 94 (3) , 337-347
Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors
Background: A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of multiple doses of modafinil, a moderate CYP3A4 inducer at a 400 mg QD dose, on the multiple oral dose pharmacokinetics (PK) of encorafenib and its metabolite, LHY746 and binimetinib and its metabolite, AR00426032. Methods: This study was conducted in patients with BRAF V600-mutant advanced solid tumors. Treatment of 400 mg QD modafinil was given on Day 15 through Day 21. Encorafenib 450 mg QD and binimetinib 45 mg BID were administered starting on Day 1. PK sampling was conducted from 0 to 8 h on Day 14 and Day 21. Exposure parameters were calculated for each patient by noncompartmental analysis and geometric least-squares mean ratio. Corresponding 90% confidence intervals were calculated to estimate the magnitude of effects. Results: Among 11 PK evaluable patients, encorafenib Cmax and AUClast were decreased in presence of steady-state modafinil by 20.2% and 23.8%, respectively. LHY746 exposures were not substantially changed in the presence of steady-state modafinil. Conclusion: The results from this clinical study indicate modafinil 400 mg QD had a weak effect on encorafenib PK. Based on these results, encorafenib can be coadministered with a moderate CYP3A4 inducer without dosing adjustment. Clinical trial registration: ClinicalTrials.gov NCT03864042, registered 6 March 2019.
- 15 June 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 94 (3) , 337-347
Open AccessEvaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors
Background: A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of multiple doses of modafinil, a moderate CYP3A4 inducer at a 400 mg QD dose, on the multiple oral dose pharmacokinetics (PK) of encorafenib and its metabolite, LHY746 and binimetinib and its metabolite, AR00426032. Methods: This study was conducted in patients with BRAF V600-mutant advanced solid tumors. Treatment of 400 mg QD modafinil was given on Day 15 through Day 21. Encorafenib 450 mg QD and binimetinib 45 mg BID were administered starting on Day 1. PK sampling was conducted from 0 to 8 h on Day 14 and Day 21. Exposure parameters were calculated for each patient by noncompartmental analysis and geometric least-squares mean ratio. Corresponding 90% confidence intervals were calculated to estimate the magnitude of effects. Results: Among 11 PK evaluable patients, encorafenib Cmax and AUClast were decreased in presence of steady-state modafinil by 20.2% and 23.8%, respectively. LHY746 exposures were not substantially changed in the presence of steady-state modafinil. Conclusion: The results from this clinical study indicate modafinil 400 mg QD had a weak effect on encorafenib PK. Based on these results, encorafenib can be coadministered with a moderate CYP3A4 inducer without dosing adjustment. Clinical trial registration: ClinicalTrials.gov NCT03864042, registered 6 March 2019.
- Open Access
- 29 February 2024
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 63 (4) , 483-496
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
Background and Objectives Encorafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma or metastatic colorectal cancer, respectively, with selected BRAF V600 mutations. A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of encorafenib on rosuvastatin, a sensitive substrate of OATP1B1/3 and breast cancer resistance protein (BCRP), and bupropion, a sensitive CYP2B6 substrate. Coproporphyrin I (CP-I), an endogenous substrate for OATP1B1, was measured in a separate study to deconvolute the mechanism of transporter DDI. Methods DDI study participants received a single oral dose of rosuvastatin (10 mg) and bupropion (75 mg) on days − 7, 1, and 14 and continuous doses of encorafenib (450 mg QD) and binimetinib (45 mg BID) starting on day 1. The CP-I data were collected from participants in a phase 3 study who received encorafenib (300 mg QD) and cetuximab (400 mg/m2 initial dose, then 250 mg/m2 QW). Pharmacokinetic and pharmacodynamic analysis was performed using noncompartmental and compartmental methods. Results Bupropion exposure was not increased, whereas rosuvastatin Cmax and area under the receiver operating characteristic curve (AUC) increased approximately 2.7 and 1.6-fold, respectively, following repeated doses of encorafenib and binimetinib. Increase in CP-I was minimal, suggesting that the primary effect of encorafenib on rosuvastatin is through BCRP. Categorization of statins on the basis of their metabolic and transporter profile suggests pravastatin would have the least potential for interaction when coadministered with encorafenib. Conclusion The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib. Clinical Trial Registration ClinicalTrials.gov NCT03864042, registered 6 March 2019.
- 29 February 2024
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 63 (4) , 483-496
Open AccessClinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
Background and Objectives Encorafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma or metastatic colorectal cancer, respectively, with selected BRAF V600 mutations. A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of encorafenib on rosuvastatin, a sensitive substrate of OATP1B1/3 and breast cancer resistance protein (BCRP), and bupropion, a sensitive CYP2B6 substrate. Coproporphyrin I (CP-I), an endogenous substrate for OATP1B1, was measured in a separate study to deconvolute the mechanism of transporter DDI. Methods DDI study participants received a single oral dose of rosuvastatin (10 mg) and bupropion (75 mg) on days − 7, 1, and 14 and continuous doses of encorafenib (450 mg QD) and binimetinib (45 mg BID) starting on day 1. The CP-I data were collected from participants in a phase 3 study who received encorafenib (300 mg QD) and cetuximab (400 mg/m2 initial dose, then 250 mg/m2 QW). Pharmacokinetic and pharmacodynamic analysis was performed using noncompartmental and compartmental methods. Results Bupropion exposure was not increased, whereas rosuvastatin Cmax and area under the receiver operating characteristic curve (AUC) increased approximately 2.7 and 1.6-fold, respectively, following repeated doses of encorafenib and binimetinib. Increase in CP-I was minimal, suggesting that the primary effect of encorafenib on rosuvastatin is through BCRP. Categorization of statins on the basis of their metabolic and transporter profile suggests pravastatin would have the least potential for interaction when coadministered with encorafenib. Conclusion The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib. Clinical Trial Registration ClinicalTrials.gov NCT03864042, registered 6 March 2019.
- Open Access
- 10 April 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (5) , 2589-2599
Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach
- 10 April 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (5) , 2589-2599
Open AccessEffect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach
- Open Access
- 23 February 2022
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 42 (3) , 221-235
The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
Background and Objective Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To evaluate the effect of hepatic impairment on the pharmacokinetics of dacomitinib, two dedicated studies were conducted to inform optimal dosing. Methods Study 1 (NCT01571388) evaluated the effect of mild and moderate hepatic impairment on the plasma pharmacokinetics, safety, and tolerability after a single oral dose of dacomitinib 30 mg, and Study 2 (NCT03865446) evaluated the same endpoints in a severe hepatic impairment population. Both studies were phase I, open-label, parallel-group studies. A one-way analysis of variance (ANOVA) with unequal variance assumption and hepatic impairment group as a fixed effect was used to compare the natural log of area under the plasma concentration-time curve extrapolated to infinite time (AUCinf), AUC from time zero to the last quantifiable concentration (AUClast), and maximum plasma concentration (Cmax) for each hepatic impairment group to the respective normal hepatic function group. Since dacomitinib is a cytochrome P450 (CYP) 2D6 substrate, only participants with extensive or intermediate CYP2D6 phenotypes were included in the primary analysis. Results The AUCinf for participants with mild, moderate, or severe hepatic impairment decreased by 6%, decreased by 23%, and increased by 4%, respectively, compared with normal hepatic function, while the Cmax for participants with mild, moderate, or severe hepatic impairment increased by 3%, decreased by 20%, and increased by 31%, respectively, compared with normal hepatic function. A single oral dose of dacomitinib 30 mg was well tolerated in all participants. Conclusion Based on these pharmacokinetic results, dacomitinib pharmacokinetics of participants with mild, moderate, or severe hepatic impairment were not statistically different relative to participants with normal hepatic function based on the ANOVA analysis. No dacomitinib dose adjustments for patients with hepatic impairment are recommended. Clinical Trial Registration ClinicalTrials.gov NCT01571388, registered 5 April 2012; ClinicalTrials.gov NCT03865446, registered 6 March 2019.
- 23 February 2022
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 42 (3) , 221-235
Open AccessThe Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
Background and Objective Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To evaluate the effect of hepatic impairment on the pharmacokinetics of dacomitinib, two dedicated studies were conducted to inform optimal dosing. Methods Study 1 (NCT01571388) evaluated the effect of mild and moderate hepatic impairment on the plasma pharmacokinetics, safety, and tolerability after a single oral dose of dacomitinib 30 mg, and Study 2 (NCT03865446) evaluated the same endpoints in a severe hepatic impairment population. Both studies were phase I, open-label, parallel-group studies. A one-way analysis of variance (ANOVA) with unequal variance assumption and hepatic impairment group as a fixed effect was used to compare the natural log of area under the plasma concentration-time curve extrapolated to infinite time (AUCinf), AUC from time zero to the last quantifiable concentration (AUClast), and maximum plasma concentration (Cmax) for each hepatic impairment group to the respective normal hepatic function group. Since dacomitinib is a cytochrome P450 (CYP) 2D6 substrate, only participants with extensive or intermediate CYP2D6 phenotypes were included in the primary analysis. Results The AUCinf for participants with mild, moderate, or severe hepatic impairment decreased by 6%, decreased by 23%, and increased by 4%, respectively, compared with normal hepatic function, while the Cmax for participants with mild, moderate, or severe hepatic impairment increased by 3%, decreased by 20%, and increased by 31%, respectively, compared with normal hepatic function. A single oral dose of dacomitinib 30 mg was well tolerated in all participants. Conclusion Based on these pharmacokinetic results, dacomitinib pharmacokinetics of participants with mild, moderate, or severe hepatic impairment were not statistically different relative to participants with normal hepatic function based on the ANOVA analysis. No dacomitinib dose adjustments for patients with hepatic impairment are recommended. Clinical Trial Registration ClinicalTrials.gov NCT01571388, registered 5 April 2012; ClinicalTrials.gov NCT03865446, registered 6 March 2019.